Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
Share this article TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ -- Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN...
United Kingdom United States David Weinreich Mark Hudson Regeneron Pharmaceuticals Inc Us Department Of Health
Source: prnewswire.com